Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Suggestions for regulatory agency approval of second-line systemic therapy for metastatic transitional cell carcinoma.

× No keyword cloud information.

4 in total

1. Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials.

Authors: Guru Sonpavde; Gregory R Pond; Ronan Fougeray; Toni K Choueiri; Angela Q Qu; David J Vaughn; Guenter Niegisch; Peter Albers; Nicholas D James; Yu-Ning Wong; Yoo-Joung Ko; Srikala S Sridhar; Matthew D Galsky; Daniel P Petrylak; Ulka N Vaishampayan; Awais Khan; Nicholas J Vogelzang; Tomasz M Beer; Walter M Stadler; Peter H O'Donnell; Cora N Sternberg; Jonathan E Rosenberg; Joaquim Bellmunt
Journal: Eur Urol Date: 2012-11-26 Impact factor: 20.096

2. Do patients with metastatic urothelial carcinoma benefit from docetaxel as second-line chemotherapy?

Authors: R Morales-Barrera; C Suárez; C Valverde; I Nuñez; X Maldonado; J Morote; J Carles
Journal: Clin Transl Oncol Date: 2013-04-20 Impact factor: 3.405

Review 3. A comprehensive overview of targeted therapy in metastatic renal cell carcinoma.

Authors: Z Mihaly; Z Sztupinszki; P Surowiak; B Gyorffy
Journal: Curr Cancer Drug Targets Date: 2012-09 Impact factor: 3.428

4. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) as second-line therapy for patients with advanced urothelial cancer.

Authors: Sheng Zhang; Hongxi Xue; Qiang Chen
Journal: Oncotarget Date: 2016-09-06

4 in total